melatonin has been researched along with Cardiac Hypertrophy in 13 studies
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Emerging evidence suggests pleiotropic roles of melatonin in cardiac disease; however, the effects of melatonin on physiological vs pathological cardiac hypertrophy remain unknown." | 7.91 | Melatonin differentially regulates pathological and physiological cardiac hypertrophy: Crucial role of circadian nuclear receptor RORα signaling. ( Gao, L; Gao, Y; Ji, Q; Lan, F; Pu, J; Sheng, X; Su, Y; Tong, R; Wu, F; Xu, L; Yan, Y; Ying, X; Yuan, A; Zhao, Y, 2019) |
| "Melatonin, a circadian molecule secreted by the pineal gland, confers a protective role against cardiac hypertrophy induced by hyperthyroidism, chronic hypoxia, and isoproterenol." | 7.85 | Melatonin protects against the pathological cardiac hypertrophy induced by transverse aortic constriction through activating PGC-1β: In vivo and in vitro studies. ( Chen, X; Duan, W; Jin, Z; Jing, L; Li, B; Li, K; Liang, H; Liu, J; Liu, Z; Reiter, RJ; Ren, K; Yang, J; Yang, Y; Yi, D; Yi, W; Yu, B; Yu, S; Zhai, M; Zhang, B; Zhang, M, 2017) |
| " This study investigated whether melatonin prevents LV remodeling and improves survival in isoproterenol-induced heart failure." | 7.80 | Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure. ( Adamcova, M; Bednarova, KR; Celec, P; Gajdosechova, L; Hrenak, J; Kamodyova, N; Krajcirovicova, K; Simko, F; Zorad, S, 2014) |
| "Melatonin has been demonstrated to ameliorate cardiac hypertrophy and its accompanied fibrosis in previous studies." | 5.56 | A Peptide-Functionalized Magnetic Nanoplatform-Loaded Melatonin for Targeted Amelioration of Fibrosis in Pressure Overload-Induced Cardiac Hypertrophy. ( Cao, F; Lei, C; Liu, L; Wang, B; Wang, J; Wang, X; Yang, Q; Yuan, J; Zhang, J; Zhao, X; Zhu, X, 2020) |
| "Melatonin treatment for 8 weeks markedly attenuated cardiac hypertrophy and restored impaired cardiac function, as indicated by a decreased HW/BW ratio, reduced cell cross-sectional area and fibrosis, downregulated the mRNA levels of ANP, BNP, and β-MHC and ameliorated adverse effects on the LVEF and LVFS." | 5.56 | Melatonin ameliorates pressure overload-induced cardiac hypertrophy by attenuating Atg5-dependent autophagy and activating the Akt/mTOR pathway. ( Ding, P; Fan, ZG; Gao, EH; Kong, LH; Liu, Y; Xu, CN; Yang, J; Yang, LF, 2020) |
| "Heart failure patients have elevated arginine vasopressin (AVP) levels, which are involved in inducing peripheral vasoconstriction and cardiac hypertrophy." | 4.12 | Melatonin alleviates arginine vasopressin-induced cardiomyocyte apoptosis via increasing Mst1-Nrf2 pathway activity to reduce oxidative stress. ( Chen, S; Du, GQ; Fu, S; Li, H; Li, Y; Sun, P; Tian, J; Wang, C, 2022) |
| " Emerging evidence suggests pleiotropic roles of melatonin in cardiac disease; however, the effects of melatonin on physiological vs pathological cardiac hypertrophy remain unknown." | 3.91 | Melatonin differentially regulates pathological and physiological cardiac hypertrophy: Crucial role of circadian nuclear receptor RORα signaling. ( Gao, L; Gao, Y; Ji, Q; Lan, F; Pu, J; Sheng, X; Su, Y; Tong, R; Wu, F; Xu, L; Yan, Y; Ying, X; Yuan, A; Zhao, Y, 2019) |
| "Melatonin, a circadian molecule secreted by the pineal gland, confers a protective role against cardiac hypertrophy induced by hyperthyroidism, chronic hypoxia, and isoproterenol." | 3.85 | Melatonin protects against the pathological cardiac hypertrophy induced by transverse aortic constriction through activating PGC-1β: In vivo and in vitro studies. ( Chen, X; Duan, W; Jin, Z; Jing, L; Li, B; Li, K; Liang, H; Liu, J; Liu, Z; Reiter, RJ; Ren, K; Yang, J; Yang, Y; Yi, D; Yi, W; Yu, B; Yu, S; Zhai, M; Zhang, B; Zhang, M, 2017) |
| " This study investigated whether melatonin prevents LV remodeling and improves survival in isoproterenol-induced heart failure." | 3.80 | Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure. ( Adamcova, M; Bednarova, KR; Celec, P; Gajdosechova, L; Hrenak, J; Kamodyova, N; Krajcirovicova, K; Simko, F; Zorad, S, 2014) |
| "Melatonin has been demonstrated to ameliorate cardiac hypertrophy and its accompanied fibrosis in previous studies." | 1.56 | A Peptide-Functionalized Magnetic Nanoplatform-Loaded Melatonin for Targeted Amelioration of Fibrosis in Pressure Overload-Induced Cardiac Hypertrophy. ( Cao, F; Lei, C; Liu, L; Wang, B; Wang, J; Wang, X; Yang, Q; Yuan, J; Zhang, J; Zhao, X; Zhu, X, 2020) |
| "Melatonin treatment for 8 weeks markedly attenuated cardiac hypertrophy and restored impaired cardiac function, as indicated by a decreased HW/BW ratio, reduced cell cross-sectional area and fibrosis, downregulated the mRNA levels of ANP, BNP, and β-MHC and ameliorated adverse effects on the LVEF and LVFS." | 1.56 | Melatonin ameliorates pressure overload-induced cardiac hypertrophy by attenuating Atg5-dependent autophagy and activating the Akt/mTOR pathway. ( Ding, P; Fan, ZG; Gao, EH; Kong, LH; Liu, Y; Xu, CN; Yang, J; Yang, LF, 2020) |
| "Melatonin treatment significantly mitigated the calcium handling in the hypoxic rats by preserving SERCA expression." | 1.35 | Melatonin ameliorates calcium homeostasis in myocardial and ischemia-reperfusion injury in chronically hypoxic rats. ( Fung, ML; Hung, MW; Yeung, HM, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S | 1 |
| Li, Y | 2 |
| Fu, S | 1 |
| Wang, C | 1 |
| Sun, P | 1 |
| Li, H | 1 |
| Tian, J | 1 |
| Du, GQ | 1 |
| Zhao, X | 1 |
| Wang, X | 1 |
| Wang, J | 1 |
| Yuan, J | 1 |
| Zhang, J | 1 |
| Zhu, X | 1 |
| Lei, C | 1 |
| Yang, Q | 1 |
| Wang, B | 1 |
| Cao, F | 1 |
| Liu, L | 1 |
| Xu, CN | 1 |
| Kong, LH | 1 |
| Ding, P | 1 |
| Liu, Y | 1 |
| Fan, ZG | 1 |
| Gao, EH | 1 |
| Yang, J | 2 |
| Yang, LF | 1 |
| Yang, Y | 3 |
| Du, J | 1 |
| Xu, R | 1 |
| Shen, Y | 1 |
| Yang, D | 1 |
| Hu, H | 1 |
| Pei, H | 1 |
| Zhai, M | 1 |
| Liu, Z | 1 |
| Zhang, B | 1 |
| Jing, L | 1 |
| Li, B | 1 |
| Li, K | 1 |
| Chen, X | 1 |
| Zhang, M | 1 |
| Yu, B | 1 |
| Ren, K | 1 |
| Yi, W | 1 |
| Liu, J | 1 |
| Yi, D | 1 |
| Liang, H | 1 |
| Jin, Z | 1 |
| Reiter, RJ | 2 |
| Duan, W | 1 |
| Yu, S | 1 |
| Ali, T | 1 |
| Mushtaq, I | 1 |
| Maryam, S | 1 |
| Farhan, A | 1 |
| Saba, K | 1 |
| Jan, MI | 1 |
| Sultan, A | 1 |
| Anees, M | 1 |
| Duygu, B | 1 |
| Hamera, S | 1 |
| Tabassum, S | 1 |
| Javed, Q | 1 |
| da Costa Martins, PA | 1 |
| Murtaza, I | 1 |
| Xu, L | 1 |
| Su, Y | 1 |
| Zhao, Y | 1 |
| Sheng, X | 1 |
| Tong, R | 1 |
| Ying, X | 1 |
| Gao, L | 1 |
| Ji, Q | 1 |
| Gao, Y | 1 |
| Yan, Y | 1 |
| Yuan, A | 1 |
| Wu, F | 1 |
| Lan, F | 1 |
| Pu, J | 1 |
| Simko, F | 2 |
| Paulis, L | 1 |
| Bednarova, KR | 1 |
| Krajcirovicova, K | 1 |
| Hrenak, J | 1 |
| Celec, P | 1 |
| Kamodyova, N | 1 |
| Gajdosechova, L | 1 |
| Zorad, S | 1 |
| Adamcova, M | 1 |
| Lu, Q | 1 |
| Yi, X | 1 |
| Cheng, X | 1 |
| Sun, X | 1 |
| Yang, X | 1 |
| Xie, S | 1 |
| Deng, Y | 1 |
| Pan, YY | 1 |
| Wang, ZH | 1 |
| Ren, J | 1 |
| Guo, XL | 1 |
| Yuan, X | 1 |
| Shang, J | 1 |
| Liu, HG | 1 |
| Manchester, LC | 1 |
| Fuentes-Broto, L | 1 |
| Tan, DX | 1 |
| Yeung, HM | 1 |
| Hung, MW | 1 |
| Fung, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Intervention Effect Of Melatonin On The Risk Of Cardiovascular Events And Malignant Tumors In The Elderly: A Prospective, Randomized Parallel Controlled Study Based On Large Cohorts[NCT04631341] | 10,000 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for melatonin and Cardiac Hypertrophy
| Article | Year |
|---|---|
Cardiac hypertrophy and remodelling: pathophysiological consequences and protective effects of melatonin.
Topics: Animals; Cardiomegaly; Hypertension; Melatonin; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2010 |
12 other studies available for melatonin and Cardiac Hypertrophy
| Article | Year |
|---|---|
Melatonin alleviates arginine vasopressin-induced cardiomyocyte apoptosis via increasing Mst1-Nrf2 pathway activity to reduce oxidative stress.
Topics: Apoptosis; Arginine Vasopressin; Cardiomegaly; Humans; Melatonin; Myocytes, Cardiac; NF-E2-Related F | 2022 |
A Peptide-Functionalized Magnetic Nanoplatform-Loaded Melatonin for Targeted Amelioration of Fibrosis in Pressure Overload-Induced Cardiac Hypertrophy.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Drug Delivery Systems; Ferrosoferric Oxide; Fibrosis; | 2020 |
Melatonin ameliorates pressure overload-induced cardiac hypertrophy by attenuating Atg5-dependent autophagy and activating the Akt/mTOR pathway.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Cardiomegaly; Disease Models, Animal; Fi | 2020 |
Melatonin alleviates angiotensin-II-induced cardiac hypertrophy via activating MICU1 pathway.
Topics: Angiotensin II; Animals; Antioxidants; Calcium-Binding Proteins; Cardiomegaly; Disease Models, Anima | 2020 |
Melatonin protects against the pathological cardiac hypertrophy induced by transverse aortic constriction through activating PGC-1β: In vivo and in vitro studies.
Topics: Angiotensin II; Animals; Antioxidants; Cardiomegaly; Disease Models, Animal; Drug Evaluation, Precli | 2017 |
Interplay of N acetyl cysteine and melatonin in regulating oxidative stress-induced cardiac hypertrophic factors and microRNAs.
Topics: Acetylcysteine; Animals; Cardiomegaly; Cell Line; Disease Models, Animal; Free Radical Scavengers; G | 2019 |
Melatonin differentially regulates pathological and physiological cardiac hypertrophy: Crucial role of circadian nuclear receptor RORα signaling.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Melatonin; Mice; Mice, Mutant Strains; Nuclear Recept | 2019 |
Antifibrotic effect of melatonin--perspective protection in hypertensive heart disease.
Topics: Animals; Cardiomegaly; Fibrosis; Humans; Hypertension; Melatonin; Myocardium | 2013 |
Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure.
Topics: Animals; Cardiomegaly; Heart Failure; Isoproterenol; Male; Melatonin; Rats; Rats, Wistar | 2014 |
Melatonin protects against myocardial hypertrophy induced by lipopolysaccharide.
Topics: Animals; Calcineurin; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly; Car | 2015 |
Melatonin protects against chronic intermittent hypoxia-induced cardiac hypertrophy by modulating autophagy through the 5' adenosine monophosphate-activated protein kinase pathway.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Cardiomegaly; Cardiotonic Agents; Cell Line; Chro | 2015 |
Melatonin ameliorates calcium homeostasis in myocardial and ischemia-reperfusion injury in chronically hypoxic rats.
Topics: Animals; Antioxidants; Blotting, Western; Calcium; Cardiomegaly; Cells, Cultured; Hematocrit; Homeos | 2008 |